394 related articles for article (PubMed ID: 33539004)
1. The metabolic profiles and body composition of lean metabolic associated fatty liver disease.
Cheng YM; Kao JH; Wang CC
Hepatol Int; 2021 Apr; 15(2):405-412. PubMed ID: 33539004
[TBL] [Abstract][Full Text] [Related]
2. The metabolic profiles and body composition of non-obese metabolic associated fatty liver disease.
Zhang Y; Xiang L; Qi F; Cao Y; Zhang W; Lv T; Zhou X
Front Endocrinol (Lausanne); 2024; 15():1322563. PubMed ID: 38375190
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
[TBL] [Abstract][Full Text] [Related]
4. Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants.
Chang M; Shao Z; Shen G
BMJ Open; 2023 May; 13(5):e070189. PubMed ID: 37130686
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort.
Zeng J; Jin Q; Yang J; Yang RX; Zhang RN; Zhao J; Fan JG
Hepatol Int; 2023 Dec; 17(6):1416-1428. PubMed ID: 37728728
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Lean Patients with Non-alcoholic Fatty Liver Disease in a Middle Income Country; Prevalence and Its Association with Metabolic Disorders: A Cross-sectional Study.
Naderian M; Kolahdoozan S; Sharifi AS; Garmaroudi G; Yaseri M; Poustchi H; Sohrabpour AA
Arch Iran Med; 2017 Apr; 20(4):211-217. PubMed ID: 28412824
[TBL] [Abstract][Full Text] [Related]
9. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: A retrospective case-control study.
Liu J; Duan S; Wang C; Wang Y; Peng H; Niu Z; Yao S
Front Endocrinol (Lausanne); 2022; 13():1035418. PubMed ID: 36531447
[TBL] [Abstract][Full Text] [Related]
10. Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women.
Lu Y; Ge L; Yang H; He Y; Wang Y
Diabetes Metab Syndr Obes; 2023; 16():607-617. PubMed ID: 36909348
[TBL] [Abstract][Full Text] [Related]
11. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China.
Li H; Guo M; An Z; Meng J; Jiang J; Song J; Wu W
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32168920
[TBL] [Abstract][Full Text] [Related]
13. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
15. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
16. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
[TBL] [Abstract][Full Text] [Related]
17. Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease.
Wang H; Zhang Y; Liu Y; Li H; Xu R; Fu H; Yan C; Qu B
Front Endocrinol (Lausanne); 2023; 14():1163682. PubMed ID: 37152940
[TBL] [Abstract][Full Text] [Related]
18. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease.
Duan SJ; Ren ZY; Zheng T; Peng HY; Niu ZH; Xia H; Chen JL; Zhou YC; Wang RR; Yao SK
World J Gastroenterol; 2022 Sep; 28(36):5364-5379. PubMed ID: 36185625
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.
Zeng J; Yang RX; Sun C; Pan Q; Zhang RN; Chen GY; Hu Y; Fan JG
World J Gastroenterol; 2020 Apr; 26(15):1792-1804. PubMed ID: 32351294
[TBL] [Abstract][Full Text] [Related]
20. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
